Pharmaceutical

BioVersys and Shionogi agree to develop ansamycin leads

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.

Jul 5, 2025 - 06:00
BioVersys and Shionogi agree to develop ansamycin leads
BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.
Read the original article

Tags:

Previous Article

UK Government reveals 10-year plan for NHS

Next Article

Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Pumping milk at JPM was a nightmare. It’s part of a bigger problem in the industry

Opinion: Pumping milk at JPM was a nightmare. It’s part...

Jan 12, 2024

Drug Farm candidate gains rare paediatric disease status  

Drug Farm candidate gains rare paediatric disease status  

Jan 15, 2024

A looming penicillin shortage threatens pregnant adults with syphilis and their newborns

A looming penicillin shortage threatens pregnant adults...

Jun 22, 2023